Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use

Urology

Volumn 83, Issue 6, 2014, Pages 1334-1338

  Romero Otero, Javier ^a   García Gómez, Borja ^a   Medina Polo, José ^a   Jiménez Alcaide, Estíbaliz ^a   García Cruz, Eduardo ^b   Sallent Font, Andrea ^b   Rodríguez Antolín, Alfredo ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b REISHO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V;

ADULT; ARTICLE; EDUCATION PROGRAM; ERECTILE DYSFUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION ERROR; PRIORITY JOURNAL; STRUCTURED INTERVIEW;

ADMINISTRATION, ORAL; ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MEDICATION ERRORS; MIDDLE AGED; PATIENT EDUCATION AS TOPIC; PHOSPHODIESTERASE 5 INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901625732     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2014.02.016     Document Type: Article

References (19)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence JAMA 270 1993 83 90
2. K. Hatzimouratidis, E. Amar, and I. Eardley et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation Eur Urol 57 2010 804 814
3. K. Hatzimouratidis, and D.G. Hatzichristou A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 65 2005 1621 1650
4. I. Goldstein, T.F. Lue, and H. Padma-Nathan et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group N Engl J Med 338 1998 1397 1404
5. H.O. Atiemo, M.J. Szostak, and G.N. Sklar Salvage of sildenafil failures referred from primary care physicians J Urol 170 2003 2356 2358
6. A.R. McCullough, J.H. Barada, and A. Fawzy et al. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction Urology 60 2002 28 38
7. I. Gruenwald, O. Shenfeld, and J. Chen et al. Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil Eur Urol 50 2006 134 140
8. H.A. Feldman, I. Goldstein, and D.G. Hatzichristou et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 151 1994 54 61
9. C.A. Derby, B.A. Mohr, and I. Goldstein et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 56 2000 302 306
10. G. Corona, N. Mondaini, and A. Ungar et al. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient J Sex Med 8 2011 3418 3432
11. D.H. Lau, S. Kommu, and F.H. Mumtaz et al. The management of phosphodiesterase-5 (PDE5) inhibitor failure Curr Vasc Pharmacol 4 2006 89 93
12. C.C. Carson, D.G. Hatzichristou, and S. Carrier et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial BJU Int 94 2004 1301 1309
13. M. Kendirci, O. Tanriverdi, and L. Trost et al. Management of sildenafil treatment failures Curr Opin Urol 16 2006 449 459
14. N. Mehrotra, M. Gupta, and A. Kovar et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy Int J Impot Res 19 2007 253 264
15. J. Rajfer, P.J. Aliotta, and C.P. Steidle et al. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US Int J Impot Res 19 2007 95 103
16. K. Hatzimouratidis, A.L. Burnett, and D. Hatzichristou et al. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application Eur Urol 55 2009 334 347
17. H. Porst, F. Giuliano, and S. Glina et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial Eur Urol 50 2006 351 359
18. D. Hatzichristou, M. Gambla, and E. Rubio-Aurioles et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction Diabet Med 25 2008 138 146
19. I. Goldstein, A.R. McCullough, and L.A. Jones et al. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of avanafil in subjects with erectile dysfunction J Sex Med 9 2012 1122 1133